Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123184) titled 'Clinical study of trastuzumab deruxtecan combined with stereotactic radiotherapy for the treatment of HER2-positive and HER2-low breast cancer patients with brain metastases' on April 22.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Huashan Hospital, Fudan University
Condition:
HER2-positive breast cancer brain metastases
HER2-low breast cancer brain metastases
Intervention:
HER2-low group:N/A
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-04-30
Target Sample Size: HER2-low group:20;HER2-positive group:30;
Countries of Recruitment:
China
To...